એન્ટિબાયોટિક પ્રતિકાર ખાસ કરીને ગ્રામ-નેગેટિવ બેક્ટેરિયાએ લગભગ કટોકટી જેવી સ્થિતિ સર્જી છે. નવલકથા એન્ટિબાયોટિક ઝોસુરાબાલપિન (RG6006) વચનો દર્શાવે છે. તે પૂર્વ-ક્લિનિકલ અભ્યાસોમાં ડ્રગ-પ્રતિરોધક, ગ્રામ-નેગેટિવ બેક્ટેરિયા CRAB સામે અસરકારક હોવાનું જણાયું છે.
Antimicrobial resistance (એએમઆર), driven mainly by the misuse and overuse of antimicrobials, is one of top public health risk.
Infections by Gram-negative bacteria are particularly concerning. It is not easy for most of એન્ટીબાયોટીક્સ to cross both inner and outer membranes present in this category of bacteria to enter the bacterial cells to show bactericidal actions. Also, Gram-negative bacteria have accumulated disproportionately high degree of એન્ટીબાયોટીક પ્રતિકાર.
એસિનેટોબેક્ટર બૌમનની is a Gram-negative bacterium. Infection by one of its strains called ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) is hard to treat using available એન્ટીબાયોટીક્સ. There is an urgent need for an effective એન્ટીબાયોટીક against CARB as mortality rate is high (about 40%-60%) which attributed largely to lack of an effective એન્ટીબાયોટીક. A progress towards this goal has been reported.
Scientists have identified a novel class of એન્ટીબાયોટીક્સ namely, tethered macrocyclic peptides (MCPs) which are active against the Gram –ve bacteria A. baumannii including CARB by blocking transport of bacterial lipopolysaccharide from the inner membrane to the outer membrane.
ઝોસુરાબાલપિન (RG6006) એક છે એન્ટીબાયોટીક candidate belonging to ‘tethered macrocyclic peptides (MCPs)’ class. In pre-તબીબી trials involving in vitro studies and in vivo studies on animal models, Zosurabalpin has been found to be effective against drug-resistant isolates of ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) from different regions. It successfully overcame એન્ટીબાયોટીક-resistance mechanism of CARB suggesting ઝોસુરાબાલપિન ક્ષમતા ધરાવે છે.
Hence, human તબીબી trials have been initiated to check for safety and efficacy ઝોસુરાબાલપિન CRAB દ્વારા થતા આક્રમક ચેપની સારવારમાં.
***
સંદર્ભ:
- Zampaloni, C., Mattei, P., Bleicher, K. et al. A novel એન્ટીબાયોટીક class targeting the lipopolysaccharide transporter. Nature (2024). https://doi.org/10.1038/s41586-023-06873-0
- હોઝર એસ., એટ અલ 2023. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against ક્લિનિકલ Acinetobacter Isolates from China, Open Forum Infectious Diseases, Volume 10, Issue Supplement_2, December 2023, ofad500.1754, https://doi.org/10.1093/ofid/ofad500.1754
***
